Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells.
Researchers at the Perelman School of Medicine at the University of Pennsylvania have been working on a preclinical study that focuses on a new strategy that uses a “one-two punch” to assist T cells in attacking solid tumors.
Consuming a diet rich in vitamin A or its analogs may help prevent children and young adults with acute lymphoblastic leukemia (ALL) reduce their risk of developing painful pancreas inflammation during chemotherapy treatment.
The most frequent type of malignancy in kids is acute lymphoblastic leukemia (ALL).
Blocking a protein chain reaction makes childhood leukemia cells more sensitive to an existing targeted treatment, a new study shows.
We speak to Dr. Chao Ma, one of the speakers at SLAS 2022, about his groundbreaking 'leukemia-on-a-chip' technology and its future within therapy resistance.
In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease between three and 12 months accurately identified all patients who would eventually relapse, while other methods were less predictive.
New research published today in JAMA Oncology reports how two separate DNA changes appear to predict aggressive childhood leukemias when they occur in combination.
When researchers from Penn Medicine found that many patients with B-cell acute lymphoblastic leukemia (ALL) treated with the investigational chimeric antigen receptor (CAR) T cell therapy targeting the CD22 antigen didn't respond, they went back to the drawing board to determine why.
Using a widely known field of mathematics designed mainly to study how digital and other forms of information are measured, stored and shared, scientists at Johns Hopkins Medicine and Johns Hopkins Kimmel Cancer Center say they have uncovered a likely key genetic culprit in the development of acute lymphoblastic leukemia (ALL).
UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur.
In a new study led by Yale Cancer Center, researchers have discovered a novel metabolic gatekeeper mechanism for leukemia. This mechanism depends on a molecule called PON2, which could lead to a new treatment for the disease. The findings were published online today in the Proceedings of the National Academy of Sciences (PNAS).
CAR T cells are a breakthrough class of effective but often toxic cancer therapies. To prevent overactivation, switchable CAR T cells were engineered that can be turned on and off with an approved, widely used cancer drug.
Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells' ability to eliminate blood cancers, according to new preclinical data from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center.
According to a new study, a novel T cell genetically engineered by scientists from The University of Arizona Health Sciences can target and attack pathogenic T cells that are responsible for causing Type 1 diabetes. These latest findings may result in new immunotherapy therapies.
Scientists have shown that cancer rebuilds the architecture of human chromosomes, which allows the disease to take hold and spread.
Scientists at St. Jude Children's Research Hospital are investigating the inherited genetics of childhood leukemia and how particular gene variations can affect treatment outcomes. The research showed that an inherited variation in the GATA3 gene strongly influences early response to chemotherapy and is linked to relapse in children with acute lymphoblastic leukemia (ALL).
CAR-T cell therapy, which attacks cancer cells using a person's reprogrammed immune cells, has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical trial led by researchers at UNC Lineberger Comprehensive Cancer Center and Baylor College of Medicine in Houston.
The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya's (Government of Catalonia) CERCA network, has created the OneChain Immunotherapeutics spin-off, the aim of which is to develop new immuno-oncological therapeutic tools with various preclinical candidates, based on CAR-T technology for different tumors, such as cortical T-cell acute lymphoblastic leukemia (coT-ALL), a rare subtype of leukemia that mainly affects children, and which has a poor prognosis.